OBR Daily Commentary - Colorectal

forumImage

FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

(MarketWatch) Sept 14, 2017 - Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin [®] (bevacizumab).

Howard S. Hochster, MD (Posted: September 15, 2017)

quotesFirst approval for a biosimilar in solid tumor usage! This should help bring down the cost of bev by about 1/3. Other bev biosimilars to follow. There is no approval for interchangeability with originator bev, and this must be prescribed specifically using the suffix. But this should be regarded as a step forward for patients and for control of costs. Ironically, Amgen took Novartis to the SCOTUS to delay their roll out of biosimilar filgrastim. Speak to your pharmacy committees!quotes

Read Article arrow
Add Comment 1 Comment
forumImage

New Study Determines Cancer Care Delivered In Hospital Outpatient Setting Much More Expensive Than In Independent, Community Oncology Practices

(COA) Sept 28, 2017 - Chemotherapy 71% more expensive, physician visits 333% more expensive, and patients have higher rates of emergency department visits when treated in hospital outpatient setting; data consistent across tumor types, including breast, lung, and colorectal cancers.

Jeff Patton (Posted: September 28, 2017)

quotesWe have know for years that the community setting is the lower cost site of care but have been slow perform and publish the studies to prove our case. Congratulations to Dr. Gordan and his collaborators for this publications. Hopefully as we move toward value based reimbursements patient treatment will migrate back to community oncology clinics where the cost of care is lower and patient convenience is better.quotes

Read Article arrow
Add Comment 3 Comment
forumImage

New Study Determines Cancer Care Delivered In Hospital Outpatient Setting Much More Expensive Than In Independent, Community Oncology Practices

(COA) Sept 28, 2017 - Chemotherapy 71% more expensive, physician visits 333% more expensive, and patients have higher rates of emergency department visits when treated in hospital outpatient setting; data consistent across tumor types, including breast, lung, and colorectal cancers.

Thomas Marsland, MD (Posted: October 02, 2017)

quotesI recently had the opportunity to talk with a group of medical oncologists about MACRA. Many of these physicians are still practicing in small groups or single doctor offices. At the end of the discussion I felt I had to hand out prescriptions for Zolof (a good Napa Cab had already been supplied). They were clearly overwhelmed with the rules and regulations and compliance issues in the new law. These heap additional expenses on already overburdened small practices. This report AGAIN demonstrates the cost efficiency of care delivered in the private practice setting. When physicians control the care delivery, we have continually shown that we can do a better job at cost control than care delivered in a hospital program. Hospitals have a dramatic economic advantage over private practice with things like the 340B pricing and the OPPS. They can give the oncologist greater economic security but at a larger cost for equivalent care. The powers that be must soon understand that the present system is driving doctor out of private practice and that if effort to equalize the reimbursement landscape are not changed there will be no private practices left (I suspect that is their real objective).quotes

Read Article arrow
Add Comment 3 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...